Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at TD Cowen

TD Cowen upgraded shares of Maze Therapeutics (NASDAQ:MAZE) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other research analysts have also issued reports about the company. Leerink Partners began coverage on Maze Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $28.00 target price for the company. Guggenheim assumed coverage on Maze Therapeutics in a research report on Tuesday. They set a “buy” rating and a $19.00 price objective for the company. JPMorgan Chase & Co. began coverage on Maze Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, Leerink Partnrs raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $25.67.

Maze Therapeutics Trading Up 10.7 %

MAZE stock opened at $11.70 on Tuesday. Maze Therapeutics has a 52-week low of $10.08 and a 52-week high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.